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MicroRNA-34a Modulates MDM4 Expression via a Target
Site in the Open Reading Frame
Pooja Mandke, Nicholas Wyatt, Jillian Fraser, Benjamin Bates, Steven J. Berberich, Michael P. Markey*
Department of Biochemistry and Molecular Biology, Wright State University, Dayton, Ohio, United States of America

Abstract
Background: MDM4, also called MDMX or HDMX in humans, is an important negative regulator of the p53 tumor
suppressor. MDM4 is overexpressed in about 17% of all cancers and more frequently in some types, such as colon cancer or
retinoblastoma. MDM4 is known to be post-translationally regulated by MDM2-mediated ubiquitination to decrease its
protein levels in response to genotoxic stress, resulting in accumulation and activation of p53. At the transcriptional level,
MDM4 gene regulation has been less clearly understood. We have reported that DNA damage triggers loss of MDM4 mRNA
and a concurrent increase in p53 activity. These experiments attempt to determine a mechanism for down-regulation of
MDM4 mRNA.
Methodology/Principal Findings: Here we report that MDM4 mRNA is a target of hsa-mir-34a (miR-34a). MDM4 mRNA
contains a lengthy 39 untranslated region; however, we find that it is a miR-34a site within the open reading frame (ORF) of
exon 11 that is responsible for the repression. Overexpression of miR-34a, but not a mutant miR-34a, is sufficient to decrease
MDM4 mRNA levels to an extent identical to those of known miR-34a target genes. Likewise, MDM4 protein levels are
decreased by miR-34a overexpression. Inhibition of endogenous miR-34a increased expression of miR-34a target genes and
MDM4. A portion of MDM4 exon 11 containing this 8mer-A1 miR-34a site fused to a luciferase reporter gene is sufficient to
confer responsiveness, being inhibited by additional expression of exogenous mir-34a and activated by inhibition of miR34a.
Conclusions/Significance: These data establish a mechanism for the observed DNA damage-induced negative regulation of
MDM4 and potentially provide a novel means to manipulate MDM4 expression without introducing DNA damage.
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damage response [9,10]. Localization of MDM4 to the nucleus
is also regulated, in part by p53 and MDM2, but potentially by
other proteins as well [11,12]. Recently, MDM4 was shown to
bind to the noncoding 5S rRNA [13]. This stabilizes MDM4 by
inhibiting the ability of MDM2 to ubiquitinate MDM4.
Transcriptionally, MDM4 is controlled by MAPK signaling
through the transcription factors c-Ets and Elk-1 [14]. Several
truncated alternative transcripts of MDM4 have been identified,
some of which have been shown to influence p53 activity in cancer
cells (reviewed in [15]). A recent report has shown a longer
alternative transcript of MDM4, termed HDMX-L, which
interestingly is induced by p53 from a p53 binding site between
exon 1 of the MDM4 gene and the alternative exon 1b [16].
However, full-length MDM4 mRNA transcripts have been found
to decrease in response to damage, independent of p53 status [17].
These seemingly contradictory reports have been thus far
explained by differences in the doses of DNA-damaging agents
used between the two studies. Importantly, a mechanism for
decreased MDM4 mRNA has not been demonstrated. This was
the aim of the experiments detailed here.

Introduction
The gene MDM4 has become a target of interest for therapeutic
intervention in cancer. MDM4 serves as an important negative
regulator of the p53 tumor suppressor. Through the RING
domain at the C-terminus, MDM4 binds p53 and inhibits its
ability to transcriptionally regulate gene expression. Recently,
MDM4 has been shown to play an additional role in apoptosis by
acting as a scaffold at mitochondria to bring together p53 and
BCL2 and promote apoptosis [1]. The importance of MDM4 in
human cancer is underscored by its frequent amplification in
certain tumor types, such as colon cancer [2], gliomas [3–5] and
retinoblastomas [6]. Full activation of p53 in response to DNA
damage requires inhibition of MDM4 [7]. Targeting of MDM4
represents an attractive therapeutic approach for the reactivation
of p53, especially given that restoration of p53 in the absence of
MDM4 is not lethal to normal cells [8]. It is therefore important
that we understand the mechanisms controlling MDM4 activity.
MDM4 has long been understood as a target of the closelyrelated protein MDM2. MDM2 acts an E3 ubiquitin ligase,
targeting MDM4 protein for degradation during the DNA
PLoS ONE | www.plosone.org
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MicroRNAs are short noncoding RNAs that interfere with gene
expression by binding to imperfectly complimentary mRNAs,
inducing their destruction and/or inhibiting their translation.
miR-34a has been demonstrated to be robustly induced directly by
p53 [18–22] and contribute to the pro-apoptotic effect of p53 by
down-regulating genes involved in cell survival and proliferation
(reviewed in [23,24]). Induction of miR-34a has been previously
shown to correspond to the decrease in MDM4 mRNA following
DNA damage in several cell lines [17]. Targeting of MDM4 by
miR-34a would be consistent with the pro-apoptotic effect of miR34a expression.
Here, we demonstrate that MDM4 mRNA is targeted by the
microRNA miR-34a. Expression of miR-34a varies greatly
between cell lines. Over expression of miR-34a in cells with low
endogenous levels can inhibit the expression of endogenous
MDM4 mRNA and protein. Importantly, these effects do not
seem to be mediated by the 39 untranslated region (UTR) of
MDM4. Rather, a miR-34a site in the coding region of the last
exon of MDM4 (exon 11) is sufficient to influence reporter gene
expression.

an expression plasmid encoding either miR-34a or a mutated
miR-34a that does not produce a mature microRNA [21].
Overexpression of miR-34a in MCF7 (Figure 2A) resulted in 40%
repression of MDM4 observed by RT-qPCR. Importantly, this
decrease matched closely in magnitude the repression of the
known miR-34a target genes CCND1 and CDK6 [27]. Similar
results were observed in H1299, a cell line with low endogenous
miR-34a (not shown), suggesting the effect of miR-34a was p53
independent. Overexpression of miR-34a similarly leds to a
decrease in MDM4 protein expression (Figure 2B).
In order to determine whether endogenous miR-34a inhibits
MDM4, MCF7 cells were transfected with an inhibitor of miR34a (mirVana miRNA inhibitor, Invitrogen). A reduction of nearly
80% in miR-34a levels was achieved (Figure 2C), although this
may still represent relatively high levels of miR-34a compared to
other cell lines (Figure 1A). Interestingly, inhibition of miR-34a in
MCF7 cells was able to de-repress MDM4, CCND1, or CDK6
(Figure 2D). A similar slight increase in MDM4 protein expression
was observed (Figure 2E).

Results

The 39 Untranslated Region of MDM4 does not Respond
to miR-34a
MicroRNAs are known to bind at the 39 UTR to down-regulate
target mRNAs, through degradation of the mRNA and/or
inhibition of translation. To test for regulation of MDM4 by
miR-34a, we initially created a luciferase reporter construct based
on the NCBI reference entry NM_002393.2 containing approximately 800 bp of the MDM4 39 UTR. This region showed no
response to miR-34a overexpression in MCF7, H1299, or
HCT116 (data not shown). When the NCBI reference entry for
MDM4 was updated to NM_002393.3, the 39UTR was indicated
to be much larger that the 800 bp being examined. In order to
include all the potential miR-34a sites predicted earlier [17], a
second construct containing approximately 1700 bp of the 39
UTR was generated in order to capture the region responsible for
binding miR-34a. This reporter was cotransfected into MCF7 with
expression plasmids for miR-34a or miR-34a-mut. Transfection
resulted in approximately 60% increase in miR-34a expression
compared to endogenous miR-34a levels (Figure 3A), but no
change in reporter activity (Figure 3B). To achieve a greater
overexpression of miR-34a, the experiment was repeated in
H1299. Low endogenous miR-34a allowed transfection to achieve
250-fold increase in miR-34a expression (Figure 3C). However,
this region remained completely unresponsive to miR-34a
expression in H1299 (Figure 3D).

miR-34a and MDM4 are Differentially Expressed in
Human Cell Lines
The tumor suppressor p53 is lost or mutated in about half of
human cancers [25]. In most if not all of the rest, p53 is inactivated
or held at low levels by other means. In some cancers this is
achieved through overexpression of MDM4, which binds p53 and
prevents transcription of p53 target genes. The frequency of
MDM4 overexpression varies by cancer type; for example, a
majority of retinoblastomas show amplification of MDM4 [6], but
it is very uncommon in prostate cancer [26]. In order to explore
the correlation between MDM4 expression and miR-34a expression, we surveyed a variety of cell lines for expression of each
(Figure 1). The non-small cell lung carcinoma line H1299, in
which p53 is homozygously deleted, had the lowest expression of
both MDM4 and miR-34a, although MDM4 levels could still be
reduced by treatment with doxorubicin. SAOS2 osteosarcoma
cells, also p53-null, had similarly low endogenous miR-34a and
MDM4. SAOS2 was the only line tested in which MDM4 was
slightly induced following DNA damage. Interestingly, miR-34a
remains inducible in SAOS2, indicating alternative controls on
miR-34a expression. In p53-positive cell lines MCF7 (breast
cancer) and U2OS (another osteosarcoma), miR-34a was highly
expressed; however, it was only able to be further induced
(approximately 10-fold) upon DNA damage in MCF7. Both show
a robust down-regulation of MDM4 following damage. Human
primary fibroblasts IMR90 showed high expression of miR-34a
similar to MCF7 and U2OS, no induction of miR-34a following
DNA damage, and relatively low levels of MDM4 which still
decrease after damage. This is likely due to an alternative splicing
of the MDM4 primary transcript demonstrated previously in these
cells [17]. Taken together, these data indicate that different
mechanisms may play greater or lesser roles in controlling MDM4
expression in different cell lines.

The MDM4 Open Reading Frame Contains a Functional
miR-34a Site
To determine whether the observed repression of endogenous
MDM4 was an indirect effect, the 39 UTR of MDM4 was
reexamined with improved microRNA site prediction software.
The August 2010 release of miRanda [28] did not identify any of
the miR-34a sites suspected previously in the 39 UTR of MDM4.
However, a very strong candidate site was predicted just upstream
of the 39 UTR, within the protein coding region of exon 11
(Figure 4A). This site has an exact match to the miR-34a seed site
at position 2–8 and an A in position 1, defining an 8mer-A1 site
[29]. This also matches the seed sequence used by CDK6 and
CCND1. Although exon 11 encodes the C-terminal RING
domain of MDM4, and this region is also found in the related
protein MDM2, it is interesting to note that MDM2 contains a
different codon at the homologous region which destroys the miR34a seed sequence. This locus, especially the miR-34a seed region,

Over Expression of miR-34a Inhibits Expression of known
Targets and MDM4
In order to explore the effect of miR-34a on MDM4 expression,
we used a cell line with high endogenous MDM4 and miR-34a
(MCF7). In MCF7 cells miR34a could be induced and MDM4
could be repressed following DNA damage by doxorubicin
treatment (Figure 1). These cells were transiently transfected with
PLoS ONE | www.plosone.org
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Figure 1. MDM4 and miR-34a are differently expressed in human cell lines. (A) Real-time quantitative PCR was performed in quadruplicate
for miR-34a using RNA extracted from the indicated cell lines before and after treatment with 0.5 ug/ml doxorubicin for 24 hours. Y-axis is log base
10. Error bars show 95% confidence intervals. Double asterisks indicate paired, one-tailed t-test values ,0.01 comparing the untreated to doxorubicin
treated condition for each cell line. (B) RT-qPCR as before, for MDM4.
doi:10.1371/journal.pone.0042034.g001

is fairly well conserved in MDM4 from other species, with the
chimpanzee and Xenopus genes being the only exceptions in the
sequences we compared (Figure 4A). The seed sequence in human
MDM4 is also potentially disrupted by a single nucleotide
polymorphism (SNP, rs79824231) of currently unknown frequency
in the human population.
To determine whether this ORF site is functional, the predicted
miR-34a site was inserted downstream of luciferase in a reporter
vector. In MCF7 cells with high endogenous miR-34a, knock-

PLoS ONE | www.plosone.org

down of miR-34a (Figure 2D) resulted in an increase in reporter
activity (Figure 4B). Conversely, when transfected into H1299 cells
with low endogenous miR-34a, luciferase expression was significantly repressed by miR-34a overexpression (Figure 4C). Thus, the
miR-34a site in the coding region of MDM4 exon 11 is functional
and responsive to miR-34a. Interestingly, all responsiveness to
miR-34a can be abolished by the A to C transversion found in
rs79824231. The A allele was confirmed by sequencing in all cell
lines used in this study.
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Figure 2. Endogenous MDM4 is repressed by miR-34a. (A) MCF7 cells were transfected with expression plasmids for miR-34a or a control
mutant of miR-34a. Total RNA was extracted after 48 hours, and RT-qPCR was used to quantify the expression of MDM4 and the known miR-34a
target genes CDK6 and CCND1. Expression is relative to the control (miR-34a-mut) transfection condition. Data are the averages of at least three
independent experiments. Error bars show 95% confidence intervals. Asterisks and double asterisks indicate t-test values ,0.05 and ,0.01,
respectively, comparing the miR-34a expression plasmid to the control mutant. (B) MCF7 cells were transfected as in (A), and whole cell lysates used
for immunoblots to detect MDM4, p53, and beta-actin. Quantification relative to the 34a-mutant condition and normalized to actin are shown below
each panel. (C and D) MCF7 cells were transfected with an inhibitor of miR-34a (anti-miR-34a) for 48 hours. RT-qPCR was performed for miR-34a,
MDM4, and known miR-34a target genes. (E) Following transfection with miR-34a inhibitor as before, total protein was extracted and immunoblots
were performed for the indicated proteins in MCF7.
doi:10.1371/journal.pone.0042034.g002

MDM4) has been demonstrated to be decreased by miR-191, and
hence the A allele is associated with high-grade carcinomas and
higher expression of MDM4 [32]. Second, high expression of
miR-10a in acute myeloid leukemia has been shown to associate
strongly with negative regulation of MDM4, and to repress an
MDM4 39 UTR reporter [33]. It may be that these or yet other
microRNAs act to repress MDM4 in response to DNA damage in
some cell lines.
Previous results have shown a decrease in expression of fulllength MDM4 mRNA (flMDM4) in immortal and primary cell
lines following treatment with DNA damaging agents doxorubicin
or cisplatin [17]. It was speculated that multiple factors
contributed to this decrease. First, DNA damage was observed
to increase the expression of an alternative transcript of MDM4,

Discussion
Many factors influence the expression of MDM4. Copy number
can be increased or copies lost, and transcription can be influenced
by known transcription factors. Alternative splicing influences the
types of MDM4 transcripts produced, and p53 can induce at least
one alternative form in particular. Many post-translational effects
influence MDM4 protein stability and localization. Importantly,
ubiquitination by MDM2 and deubiquitination by HAUSP or
USP2a play a major role in MDM4 stability [30,31]. Even the
noncoding 5S rRNA has been shown to bind MDM4 and inhibit
ubiquitination [13]. To date, two microRNAs have been shown to
influence MDM4 expression. First, mRNA from the C allele but
not the majority A allele of rs4245739 (a SNP in the 39 UTR of

PLoS ONE | www.plosone.org
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Figure 3. The 39 UTR of MDM4 is unresponsive to miR-34a expression. Data are the averages of at least four independent experiments, with
standard deviation indicated in error bars. Double asterisks indicate paired, one-tailed t-test values ,0.01 between control and experimental
conditions. Triple asterisks indicate p-value ,0.001. (A) MCF7 cells were co-transfected with an expression plasmid for miR-34a or the nonfunctional
mutant miR-34a-mut which produces no mature miR-34a transcript [21]. Expression of miR-34a was determined by RT-qPCR. (B) Expression plasmids
for miR-34a or miR-34a-mut were co-transfected with a luciferase reporter plasmid containing approximately 1700 bp of the MDM4 39UTR
downstream of luciferase. Cell lysates were used for luciferase assays 48 hours after transfection. Expression is relative to the expression of luciferase
in the psicheck2 vector lacking a 39 UTR. The plasmid psicheck2-AS34a is a positive control for regulation by miR-34a and contains a miR-34a
response element [51]. (C and D) As above, for H1299 cells.
doi:10.1371/journal.pone.0042034.g003

prediction methods for miRNA sites failed to identify miR-34a
sites in the MDM4 39 UTR that were previously suspected [17].
Rather, a strong prediction was made within the ORF of the final
exon of MDM4. miRNA recognition of a target mRNA through
the coding region is not without precedent. Several splice variants
of the human gene DNMT1 have been shown to be regulated by
miR-148 via a site in the protein coding region [36], and this type
of targeting is common in plants [37,38]. Another example from a
human gene is human hepatocyte nuclear factor 4 alpha
(HNF4A), which is regulated by a miR-34a site in the ORF of
that gene [39]. Moreover, many functional ORF miRNA sites
have been detected, and mRNAs with an 8mer site in the ORF
were shown to be repressed by a microRNA significantly better
than mRNAs without a site [40]. Fang and Rajewsky recently
observed that mRNA repression is achieved in vivo even with only
microRNA seed sites in the coding region, although these
synergize with 39 UTR seed sites [41]. This MDM4 ORF site is
of the most highly conserved type, 8mer-Al, as defined by Jan
et al. [29]. Accordingly, the miRSVR score -1.286 corresponds to
approximately the top 2.5% of all predicted miRNA sites [28].
The predicted seed region exactly matches that used by the known
miR-34a targets CDK6 and CCND1 [27].
This miR-34a site is expected to be present in all transcript
variants of human MDM4 described to date. Exon 11 is present in
MDM4-211 [42], MDM4-A [43], MDM4-G [43], and MDM4ALT2 [44]. Even in the known transcripts with premature

XAlt2. Importantly, this increase was not stoichometrically
identical to the decrease in flMDM4. Second, flMDM4 mRNA
was seen to be less stable under DNA damage conditions, which
implicated a possible role for a miRNA targeting flMDM4. Last,
in MCF7 cells the decrease in flMDM4 was observed to correlate
with an increase in miR-34a expression. These data are consistent
with recent data demonstrating a decrease in MDM4 mRNA
following targeting of multiple components of the splicing
machinery [34]. Interestingly, this decrease in MDM4 mRNA
did not depend on alternative splicing of MDM4 primary
transcripts, underlining the role of additional mechanisms
controlling MDM4 mRNA levels (ibid). A mechanism for
regulation of MDM4 by miR-34a, however, remained to be
determined. At the same time, it has been reported that the
MDM4 gene is transcriptionally activated by p53 itself, through a
p53-responsive promoter in the first exon of the MDM4 gene [16],
which is in effect similar to the targeting of MDM2 by p53 [35].
The reason for these contradictions remains to be defined;
however, in our hands we have yet to observe a change in the
low levels of HDMX-L transcripts we observe under the
conditions used in its discovery (cell line, drug dosages, and
PCR primers).
The current data support a role for miR-34a in the regulation of
MDM4 expression through targeting a site within the MDM4
open reading frame. Potential miR-34a binding sites in the 39
UTR of MDM4 were examined and found not to represent
functional loci. Indeed, more recent and improved in silico

PLoS ONE | www.plosone.org
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Figure 4. The MDM4 open reading frame contains a functional miR-34a responsive site. (A) Binding site for miR-34a predicted in human
MDM4 mRNA by miRanda. Binding is indicated by solid lines, while wobble base pairing is indicated by a dashed line. Identity with the human MDM4
sequence is indicated by asterisks. The seed region of miR-34a, positions 2–7, are boxed. The homologous region of human MDM2 mRNA is also
shown for comparison. (B) In MCF7 cells, the miR-34a inhibitor was cotransfected with a reporter gene containing the ORF miR-34a site from MDM4
(‘‘Exon 110) or the reporter with the rs79824231 SNP (‘‘Exon 11 A.C’’). Data are the averages of at least six independent experiments, with standard
deviation indicated in error bars. Asterisks indicate t-test values ,0.5. (C) In H1299 cells, the reporters were cotransfected with an expression plasmid
for miR-34a or miR-34a-mut. Data are the averages of at least six independent experiments, with standard deviation indicated in error bars. Double
asterisks indicates paired, one-tailed t-test value ,0.01.
doi:10.1371/journal.pone.0042034.g004

pro-apoptotic effect of miR-34a on p53, as miR-34a would inhibit
expression of a negative regulator of p53.

termination codons, MDM4-S [45,46] and MDM4-ALT1 [44],
the mRNA retains exon 11.
Interestingly, this miR-34a site in the ORF of MDM4 exon 11 is
also the site of a human single nucleotide polymorphism (SNP).
This site, rs79824231, is an A.C missense mutation which
changes the codon from threonine to proline. It was identified in
the 1000 Genomes Project [47], and frequency data in human
populations remains to be determined. A second SNP two bases
upstream, rs80287024 (T.C), was recently withdrawn by the
1000 Genomes Project due to a high false positive rate.
Nevertheless, we genotyped both of these sites in the cell lines
MCF7, H1299, SAOS2, and HCT116. The majority A allele was
found each case. From the location of rs79824231 within the seed
region used by miR-34a, the C allele would be expected to disrupt
recognition by miR-34a, and indeed this was our finding by
reporter assays (Figure 4C and D). The C allele would then be
expected to be present in a subset of cell lines in which MDM4
does not respond to miR-34a. A similar phenomenon has been
described in HNF4A, which also has a miR-34a site in the ORF
destroyed by a SNP [48].
It has been previously demonstrated that p53 induces the
expression of miR-34a [18–22], and that miR-34a contributes to
the pro-apototic effect of p53. In turn, miR-34a activates p53 by
inhibiting the deacetylase SIRT1 [49]. Without SIRT1 deacetylation of p53 at K382, p53 pro-apoptotic activity remains
uncompromised [50]. Data presented here are consistent with a
PLoS ONE | www.plosone.org

Materials and Methods
Cell Culture
Colon carcinoma cell line HCT116 and human non-small cell
lung carcinoma cell line H1299 were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Atlanta Biologicals) supplemented with 10% normal calf serum. Breast cancer cell line
MCF7, IMR90 human fibroblasts, and SAOS2 and U2OS
osteosarcoma cell lines were cultured in DMEM supplemented
with 10% fetal calf serum. All cell lines were obtained from the
American Type Culture Collection.

Quantitative RT-PCR
H1299, MCF7, IMR90, SAOS2, and U2OS were treated with
doxorubicin at 0.5 mg/ml for 24 hours prior to RNA extraction
using EZNA Total RNA Extraction kit and protocols (Omega BioTek). 500 ng of total RNA was reverse transcribed, then diluted to
2.5 ng per qPCR reaction using the TaqMan Assay on Demand
system, as previously described [17].
MCF7 cells were transfected 48 hours after seeding (26105)
cells in 6 cm plates. 30 nM miRVANA hsa-miR-34a inhibitor
(Ambion) was added to the serum free media. 6 ml lipofectamine2000 was added to 50 ml serum free media. The two solutions
6
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were mixed in equal quantities and allowed to stand at room
temperature for 20 minutes. 100 ml of the resulting solution was
added to 6 cm plates containing 2.9 ml serum free media. After
5 hours of incubation the cultures were returned to DMEM media
containing 10% serum. 48 hours later the cultures were processed
for RNA extraction.
For RT-qPCR of microRNA, RNA extraction was carried out
using the TRIZOL method according to the manufacturer’s
protocol. The RNA obtained by this method was further processed
to enrich for microRNA using the RT2qPCR Grade miRNA
Isolation Kit (SAbiosciences) according to manufacturer’s protocol. 10 ng of the microRNA was reverse transcribed using
miRNA-specific primers for hsa-miR-34a or hsa-mir213 (to
normalize) according to the TaqManH MicroRNA Reverse
Transcription Kit (Applied Biosystems). qPCR was performed
using TaqManH Universal PCR Master Mix (Applied Biosystems)
and the suggested protocols.

separation the proteins were transferred onto a PVDF membrane
(at 400 milliamps for 1 hour). This was followed by blocking with
5% milk in Tris-buffered saline-tween 20 (TBST) for one hour and
probing with the relevant primary antibody overnight. Following 2
thirty minute washes with TBST, a horse radish peroxidase (HRP)
conjugated secondary antibody was added for 1 hour and the
protein band was observed following addition of Super signal West
Pico chemiluminescent substrate (Thermo Scientific). The following antibodies were used: HdmX/Mdm4 A300-287A (Bethyl labs),
actin AC-40 (Sigma), p53 FL393 (Santa Cruz Technology), antirabbit IgG HRP (Promega), anti-mouse IgG HRP (Promega).
Relative quantification of western blots was performed with
ImageJ [52]. Values shown are relative to the control condition and
normalized to actin, to control for any protein loading inequalities.

Cloning
miR-34a sites were predicted by the August 2010 release of
miRanda [53]. For the plasmid ‘‘psicheck2-MDM4’’, the 39 UTR
region following the stop codon of MDM4 to 1,735 bp
downstream was amplified by PCR from BAC 433N15 (BACPAC
Resources Center) and inserted between SgfI and NotI sites in the
psicheck2 reporter plasmid (Promega) downstream of renilla
luciferase. Cloning primers were: sense 59- AAA AAA GCG
ATC GCA ATG CAT TTA TTC CGT TCA CTT -39 and
antisense 59- AAA AAA GCG GCC GCG GTG TAA GCA GCT
CCA GAG G -39. For the plasmid ‘‘psicheck2 Exon 11’’, a 444 bp
region of the coding region of exon 11 of the human MDM4 gene,
surrounding the putative ORF miR-34a site, was amplified by
PCR from BAC 433N15 (BACPAC Resources Center) and
inserted between SgfI and NotI sites in the psicheck2 reporter
plasmid (Promega) downstream of renilla luciferase. Cloning
primers were: sense 59- AAA AAA GCG CCT TGA GGA
AGG ATT GGT AT -39 and antisense 59- AAA AAA GCG GCC
GCA GCC CCA GCC TTC TTT AGT C -39. Identity of all
clones was verified by sequencing.
The plasmid ‘‘psicheck2 exon 11 A.C’’ was generated by sitedirected mutagenesis of the ‘‘psicheck2 exon 11’’ plasmid
according to the QuikChange II Site-Directed Mutagenesis kit
and protocol (Aligent Technologies). An A to C mutation was
generated to correspond to the human SNP rs79824231, which
lies in the seed region of the exon 11 ORF miR-34a site.
Mutagenic primers were: sense 59- CTC TCC ACG TCT GAT
ATC CCT GCC AT ACCT GAA AA -39 and antisense 59- TTT
TCA GGT ATG GCA GGG ATA TCA GAC GTG GAG AG 39. Mutation of the target site was verified by sequencing.

Reporter Assays
H1299 cells were transfected 24 hours after seeding (2.56106)
cells in 6 cm plates. The psicheck2 vector or psicheck2-ex11
reporter or psichcheck2-ex11 A.C reporter, and mir-34a
expression plasmid or mir-34a-mut expression plasmid, were
added to serum free media (final volume of 200 ml). 6ml of
lipofectamine2000 was added to 200 ml of serum free media,
which was then mixed with the plasmid DNA and incubated
30 minutes at room temperature. 400 ml of the resulting
DNA:lipid solutions were added to cells on 6 cm plates containing
2.5 ml serum free media. After 5 hours of incubation the cultures
were replaced with DMEM media containing 10% NCS. 48 hours
later the cultures were processed for the dual luciferase assay using
the Promega Dual Luciferase assay system and protocol. Samples
were normalized to luciferase expression in the vector-transfected
cells. Paired, one-tailed t-tests were used to determine significance.
The plasmid psicheck2-AS34a contains a consensus response site
for miR-34a, and was used as a positive control for response to
miR-34a overexpression or inhibition. It has been described [51].
MCF7 cells were transfected 24 hours after seeding the 24-well
plates (46104 cells/well). The reporter plasmid (0.2 mg) with or
without the hsa-miR-34a inhibitor (30 nM) and the psicheck2
(vector) plasmid (0.2 mg) with or without the inhibitor (30 nM) were
added to 50 ml of serum free DMEM media. 2 ml of lipofectamine2000 was added to 50 ml serum free DMEM media. The two
solutions were mixed in equal quantities and allowed to stand at
room temperature for 20 minutes. 100 ml of the resulting DNA:lipid
solution was added to culture plates containing 2.9 ml serum free
media. After 5 hours of incubation the serum free media was
replaced with DMEM media containing 10% FBS. 48 hours later
the cells were processed for the Dual Luciferase assay (Promega).

Sequence Alignment
Sequences were retrieved from GenBank and aligned using
ClustalW2 v2.1 [54] with default (slow) alignment settings. The
accession and version numbers for sequences used were: Mus
musculus EU568360.1, Rattus norvegicus NM_001012026.1, Xenopus
laevis NM_001088965.1, Pan troglodytes XM_003308706.1, human
MDM4 NM_002393, and human MDM2 NM_002392.3.

Immunoblotting
MCF7 cells were transfected 24 hours after seeding the 6 cm
plates (26104 cells) and treated with 30 nM miRVANA hsa-miR34a inhibitor (Ambion) as described above. 48 hours later the cells
were processed for protein extraction.
The cells were harvested from the 6 cm plates in phosphate
buffer saline (PBS) and lysed in RIPA buffer (50 mM Tris
pH = 8.0, 150 mM NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1%
SDS) (150 ul) to which was added protease inhibitor cocktail PIC
(1 ml/100 ml) and NaF (to 50 mM). The contents were mixed by
pipeting, incubated on ice for 30 minutes and centrifuged at
10,000 rpm for 5 minutes at 4uC. The supernatant was then taken
and protein concentration measured using the BioRad Protein
Assay. The proteins were separated by SDS-PAGE. After
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